Bicycle Therapeutics reported a net loss of $59.1 million for Q3 2025, an increase from $50.8 million in Q3 2024. Despite the increased loss, the company maintained a strong cash position of $648.3 million, providing a financial runway into 2028. The company also made significant progress in its clinical trials, particularly with zelenectide pevedotin, and strengthened its leadership team.

Bicycle Therapeutics posted a Q2 2025 net loss of $79.0 million on revenue of $2.9 million. Cash reserves remain strong at $721.5 million, supporting its growing clinical pipeline including zelenectide pevedotin and Bicycle Radioconjugates.

Bicycle Therapeutics reported a net loss of $60.8 million for Q1 2025, compared to a net loss of $26.6 million in the prior year period, driven by increased R&D and G&A expenses. Collaboration revenue decreased. The company ended the quarter with $793.0 million in cash and cash equivalents, extending its financial runway into the second half of 2027. Progress was made on the pipeline, including initiating a Phase 1/2 trial for zelenectide pevedotin in NECTIN4-amplified breast cancer.

Bicycle Therapeutics reported promising anti-tumor activity and a differentiated safety profile for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer. The company's cash and cash equivalents were $879.5 million as of December 31, 2024, expected to provide financial runway into 2H 2027.

Bicycle Therapeutics reported updated clinical results across its oncology pipeline, including a 45% overall response rate (ORR) for zelenectide pevedotin monotherapy and a 45% ORR for BT5528 6.5 mg/m2 every two weeks monotherapy, both in metastatic urothelial cancer. The company's cash and cash equivalents were $890.9 million as of September 30, 2024, excluding $31.7 million UK R&D tax credit received in October 2024, providing an expected financial runway into 2H 2027.

Bicycle Therapeutics reported progress in its pipeline, highlighting the profiles of Bicycle Toxin Conjugates, and strengthened its balance sheet with $555 million from a private investment. The company's cash and cash equivalents were $961.4 million as of June 30, 2024, expected to provide financial runway into 2H 2027.

Bicycle Therapeutics reported its first quarter financial results, highlighting the initiation of the Phase 2/3 Duravelo-2 registrational trial for BT8009 in metastatic urothelial cancer and progress across its pipeline.

Bicycle Therapeutics reported its Q4 and full year 2023 financial results, highlighting progress across its oncology portfolios and discovery pipeline. The company's cash and cash equivalents were $526.4 million as of December 31, 2023, expected to provide financial runway into 2026.

Bicycle Therapeutics reported their Q3 2023 financial results, highlighting alignment with the FDA on an expedited development plan for BT8009 and its selection for the FDA's CMC Development and Readiness Pilot Program. They also announced an upcoming R&D Day on December 14 to provide clinical updates for BT8009, BT5528 and BT7480.

Bicycle Therapeutics reported progress across its pipeline, including advancing BT8009, BT5528, and BT7480 in ongoing clinical trials. The company entered into strategic collaborations with Novartis, Bayer, and broadened an ongoing collaboration with DKFZ in radiopharmaceuticals. They also strengthened their balance sheet with gross proceeds from a public offering and Bayer upfront payment and enhanced their leadership team with a new CFO hire.

Bicycle Therapeutics reported encouraging Phase I dose escalation results from BT8009, showing anti-tumor activity in heavily pre-treated cancer patients. They also entered into multiple research and development collaborations to develop Bicycle® radio-conjugates, expanding their oncology strategy.

Bicycle Therapeutics reported its Q4 2022 financial results, highlighting clinical progress across its pipeline, including BT8009, BT5528, and BT7480. The company's cash position at the end of the year was $339.2 million, expected to provide financial runway into 2025.

Bicycle Therapeutics reported continued clinical progress across its pipeline and a strong balance sheet, supported by a $10 million option fee from Genentech. The company expects its financial runway to extend into 2025.

Bicycle Therapeutics reported its second quarter financial results, highlighting clinical progress across its pipeline and the expansion of its collaboration with Genentech. The company's cash and cash equivalents totaled $372.8 million as of June 30, 2022, providing a financial runway into 2025.

Bicycle Therapeutics reported interim data for the Phase I portion of the Phase I/II trial in BT8009, showing an overall response rate, or ORR, of 50% in the 5mg/m2 weekly cohort in patients with urothelial cancer and an encouraging tolerability profile. The company's cash and cash equivalents of $407.4 million as of March 31, 2022 are expected to provide financial runway through 2024.

Bicycle Therapeutics reported their Q4 2021 financial results, highlighting clinical progress across their pipeline and a strong cash position of $438.7 million expected to provide financial runway through 2024.

Bicycle Therapeutics reported financial results for the third quarter ended September 30, 2021, highlighting progress in clinical trials for BT5528 and BT8009, advancement of BT7480 into the clinic, and expansion of the Genentech collaboration.

Bicycle Therapeutics reported their Q2 2021 financial results, highlighting significant progress in company-sponsored clinical programs.

Bicycle Therapeutics reported its financial results for the first quarter ended March 31, 2021, highlighting the advancement of multiple Bicycle Toxin Conjugates® (BTCs) in the clinic and the preparation for BT7480 to enter the clinic later this year.

Bicycle Therapeutics reported their Q4 and full year 2020 financial results, highlighting the advancement of multiple Bicycle Toxin Conjugates (BTCs) in the clinic and preparation for the clinical start of their first tumor targeted immune cell agonist (TICA).

Bicycle Therapeutics reported their Q3 2020 financial results, highlighting the initiation of three clinical trials and a strengthened corporate leadership. The company's cash position was $149.8 million as of September 30, 2020.

Bicycle Therapeutics reported their financial results for the second quarter of 2020, highlighting progress towards their 2020 objectives despite challenges from the COVID-19 pandemic. They are advancing clinical trials for BT1718, BT8009 and BT5528.

Bicycle Therapeutics reported its Q1 2020 financial results, highlighting two new immuno-oncology collaborations, including a partnership with Genentech worth up to $1.7 billion. Key milestones were reached in clinical programs, such as establishing a recommended Phase II dose for BT1718 and advancing BT5528 through Phase I dose escalation.

Bicycle Therapeutics reported their Q4 and full year 2019 financial results, highlighting a transformational year marked by a successful IPO and strengthened leadership, enabling effective execution of their pipeline development strategy. They also noted two new immuno-oncology collaborations aimed at expanding their portfolio of immune cell agonists.